Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease

Upworthy

Published

ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer's disease. Neurimmune…

#zurich #switzerland #neurimmune #fda #biogen #ip #gmp #christophhock #brain #fabianbuller

Full Article